Table 1 Baseline demographics and characteristics of the study population
Characteristics and clinical outcomes | Total (n = 351) | MACE (n = 101) | No-MACE (n = 250) | P value | Bleeding (n = 18) | No-bleeding (n = 333) | P value |
|---|---|---|---|---|---|---|---|
Male sex, n (%) | 278 (79.2) | 82 (81.2) | 196 (78.4) | 0.56 | 13 (72.2) | 265 (79.6) | 0.454 |
Age(years, mean ± SD) | 58.2 ± 9.0 | 58.2 ± 8.5 | 58.3 ± 9.3 | 0.935 | 58.0 ± 8.6 | 58.2 ± 9.1 | 0.912 |
BMI (kg/m2, mean ± SD) | 28.3 ± 3.8 | 28.7 ± 3.4 | 28.4 ± 5.3 | 0.649 | 26.8 ± 3.7 | 28.3 ± 3.8 | 0.094 |
Alcohol intake, n (%) | 65 (18.5) | 14 (13.9) | 51 (20.4) | 0.153 | 2 (11.1) | 63 (18.9) | 0.544 |
Smoking, n (%) | 141 (40.2) | 33 (32.7) | 108 (43.2) | 0.069 | 6 (33.3) | 135 (40.5) | 0.544 |
SBP (mmHg, mean ± SD) | 133.3 ± 21.7 | 134.3 ± 22.2 | 132.9 ± 21.5 | 0.575 | 129.3 ± 19.4 | 135.5 ± 22.3 | 0.136 |
DBP (mmHg, mean ± SD) | 80.2 ± 13.4 | 80.2 ± 13.9 | 80.3 ± 12.3 | 0.772 | 80.7 ± 16.0 | 80.2 ± 13.3 | 0.668 |
TG (mg/dL) | 1.67 ± 0.70 | 1.72 ± 0.77 | 1.55 ± 0.48 | 0.148 | 1.46 ± 0.39 | 1.68 ± 0.71 | 0.375 |
LDL-C (mg/dL) | 2.52 ± 0.89 | 2.41 ± 0.89 | 2.57 ± 0.57 | 0.126 | 2.54 ± 0.70 | 2.52 ± 0.90 | 0.943 |
HDL-C (mg/dL) | 0.87 ± 0.23 | 0.85 ± 0.18 | 0.88 ± 0.25 | 0.314 | 0.92 ± 0.19 | 0.88 ± 0.24 | 0.509 |
TC (mg/dL) | 4.03 ± 1.06 | 3.91 ± 1.0 | 4.07 ± 1.08 | 0.234 | 4.13 ± 0.97 | 4.0 ± 1.07 | 0.649 |
ALT (IU/L) | 32.5 ± 13.6 | 29.5 ± 11.6 | 33.6 ± 15.3 | 0.206 | 24.5 ± 6.6 | 32.6 ± 17.8 | 0.222 |
AST (IU/L) | 36.9 ± 15.5 | 39.2 ± 16.5 | 35.9 ± 12.9 | 0.622 | 27.5 ± 13.7 | 37.1 ± 21.9 | 0.478 |
Creatinine (μmol/L) | 72.1 ± 17.9 | 71.7 ± 20.5 | 72.3 ± 16.8 | 0.778 | 78.4 ± 23.5 | 71.9 ± 17.4 | 0.134 |
UA (μmol/ L) | 325.0 ± 58.8 | 323.4 ± 57.5 | 325.6 ± 59.5 | 0.831 | 356.5 ± 58.1 | 325.2 ± 46.5 | 0.148 |
BG (mmol/L) | 6.49 ± 2.86 | 6.37 ± 2.47 | 6.53 ± 3.01 | 0.655 | 5.98 ± 1.98 | 6.5 ± 2.92 | 0.483 |
Clinical presentation, n (%) | |||||||
 Unstable angina | 181 (51.6) | 54 (53.5) | 127 (50.8) | 0.651 | 9 (50) | 172 (51.7) | 0.891 |
 STEMI | 114 (32.5) | 35 (34.7) | 79 (31.6) | 0.58 | 4 (22.2) | 110 (33.0) | 0.443 |
 NSTEMI | 56 (16.0) | 26 (25.7) | 30 (12.0) | 0.001* | 3 (16.7) | 53 (15.9) | 1.0 |
Final treatment, n (%) | Â | Â | Â | Â | Â | Â | Â |
 PCI | 276 (78.6) | 80 (79.2) | 196 (78.4) | 0.867 | 8 (44.4) | 268 (80.5) | 0.001* |
 CABG | 5 (1.4) | / | 5 (2.0) | 0.327 | 2 (11.1) | 3 (0.9) | 0.023* |
 Medical treatment only | 70 (19.9) | 21 (20.8) | 49 (19.6) | 0.8 | 8 (44.4) | 62 (18.6) | 0.008* |
Comorbidities, n% | |||||||
 Hypertension | 197 (56.1) | 57 (56.4) | 140 (56.0) | 0.941 | 9 (50) | 190 (57.1) | 0.556 |
 Fatty liver | 109 (31.1) | 32 (31.7) | 77 (30.8) | 0.871 | 3 (16.7) | 106 (31.8) | 0.203 |
 Diabetes mellitus | 138 (39.3) | 39 (38.6) | 99 (39.6) | 0.864 | 7 (38.9) | 131 (39.3) | 1.0 |
 Dyslipidemia | 272 (77.5) | 77 (76.2) | 195 (78) | 0.72 | 13 (72.2) | 259 (77.8) | 0.583 |
History, n (%) | Â | Â | Â | Â | Â | Â | Â |
 Previous MI | 77 (21.9) | 22 (21.8) | 55 (22.0) | 0.964 | 2 (11.1) | 75 (22.5) | 0.382 |
 Previous PCI | 44 (12.50) | 14 (13.9) | 30 (12.0) | 0.634 | 1 (5.6) | 43 (12.9) | 0.712 |
 Previous CABG | 5 (1.4) | 1 (1.0) | 4 (1.6) | 1.0 | / | 5 (2.1) | 1.0 |
Concomitant medication, n% | |||||||
 Statin | 339 (96.6) | 99 (98.0) | 240 (96.0) | 0.521 | 18 (100) | 321 (96.4) | 1.0 |
 PPI | 158 (45.0) | 46 (45.5) | 112 (44.8) | 0.899 | 9 (50) | 149 (44.7) | 0.662 |
 CCB | 85 (24.2) | 24 (23.8) | 61 (24.4) | 0.9 | 6 (33.3) | 79 (23.7) | 0.354 |
 β-Blocker | 287 (81.8) | 88 (87.1) | 199 (79.6) | 0.098 | 12 (66.7) | 275 (82.6) | 0.088 |
 Diuretics | 92 (26.2) | 32 (31.7) | 60 (24.0) | 0.138 | 5 (27.8) | 87 (26.1) | 0.877 |
 ARB or ACEI | 266 (75.8) | 73 (72.3) | 193 (77.2) | 0.330 | 10 (55.6) | 257 (77.2) | 0.036* |